These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 39103917)
1. Genetic analysis of foramen magnum meningiomas reveals AKT1 mutations uncomplicated by TRAF7 mutations. Hirano Y; Miyawaki S; Sakai Y; Teranishi Y; Okano A; Umekawa M; Hongo H; Torazawa S; Ogawa S; Komura D; Katoh H; Ikemura M; Ushiku T; Ishikawa S; Saito N Acta Neuropathol Commun; 2024 Aug; 12(1):123. PubMed ID: 39103917 [No Abstract] [Full Text] [Related]
2. Genetic characterization and mutational profiling of foramen magnum meningiomas: a multi-institutional study. Hua L; Alkhatib M; Fujio S; Alhasan B; Herold S; Zeugner S; Zolal A; Hijazi MM; Clark VE; Wakimoto H; Shankar GM; Brastianos PK; Barker FG; Cahill DP; Ren L; Eyüpoglu IY; Gong Y; Schackert G; Juratli TA J Neurosurg; 2024 Jul; 141(1):72-78. PubMed ID: 38277657 [TBL] [Abstract][Full Text] [Related]
3. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Clark VE; Erson-Omay EZ; Serin A; Yin J; Cotney J; Ozduman K; Avşar T; Li J; Murray PB; Henegariu O; Yilmaz S; Günel JM; Carrión-Grant G; Yilmaz B; Grady C; Tanrikulu B; Bakircioğlu M; Kaymakçalan H; Caglayan AO; Sencar L; Ceyhun E; Atik AF; Bayri Y; Bai H; Kolb LE; Hebert RM; Omay SB; Mishra-Gorur K; Choi M; Overton JD; Holland EC; Mane S; State MW; Bilgüvar K; Baehring JM; Gutin PH; Piepmeier JM; Vortmeyer A; Brennan CW; Pamir MN; Kiliç T; Lifton RP; Noonan JP; Yasuno K; Günel M Science; 2013 Mar; 339(6123):1077-80. PubMed ID: 23348505 [TBL] [Abstract][Full Text] [Related]
4. Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas. Hao S; Huang G; Feng J; Li D; Wang K; Wang L; Wu Z; Wan H; Zhang L; Zhang J J Neurooncol; 2019 Aug; 144(1):11-20. PubMed ID: 31177425 [TBL] [Abstract][Full Text] [Related]
5. Single-cell DNA sequencing reveals order of mutational acquisition in TRAF7/AKT1 and TRAF7/KLF4 mutant meningiomas. Dogan H; Blume C; Patel A; Jungwirth G; Sogerer L; Ratliff M; Ketter R; Herold-Mende C; Jones DTW; Wick W; Vollmuth P; Zweckberger K; Reuss D; von Deimling A; Sahm F Acta Neuropathol; 2022 Oct; 144(4):799-802. PubMed ID: 35984495 [No Abstract] [Full Text] [Related]
8. Clinical impact of targeted amplicon sequencing for meningioma as a practical clinical-sequencing system. Yuzawa S; Nishihara H; Yamaguchi S; Mohri H; Wang L; Kimura T; Tsuda M; Tanino M; Kobayashi H; Terasaka S; Houkin K; Sato N; Tanaka S Mod Pathol; 2016 Jul; 29(7):708-16. PubMed ID: 27102344 [TBL] [Abstract][Full Text] [Related]
9. Genomic analysis of non-neurofibromatosis type 2 meningiomas. Parry PV; Engh JA Neurosurgery; 2013 Jun; 72(6):N18-9. PubMed ID: 23685513 [No Abstract] [Full Text] [Related]
10. Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT. Jungwirth G; Warta R; Beynon C; Sahm F; von Deimling A; Unterberg A; Herold-Mende C; Jungk C Acta Neuropathol Commun; 2019 Aug; 7(1):140. PubMed ID: 31470906 [TBL] [Abstract][Full Text] [Related]
11. Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Reuss DE; Piro RM; Jones DT; Simon M; Ketter R; Kool M; Becker A; Sahm F; Pusch S; Meyer J; Hagenlocher C; Schweizer L; Capper D; Kickingereder P; Mucha J; Koelsche C; Jäger N; Santarius T; Tarpey PS; Stephens PJ; Andrew Futreal P; Wellenreuther R; Kraus J; Lenartz D; Herold-Mende C; Hartmann C; Mawrin C; Giese N; Eils R; Collins VP; König R; Wiestler OD; Pfister SM; von Deimling A Acta Neuropathol; 2013 Mar; 125(3):351-8. PubMed ID: 23404370 [TBL] [Abstract][Full Text] [Related]
12. Association of frequent NF2 mutations with spinal location predominance and worse outcomes in psammomatous meningiomas. Ren L; Xie Q; Deng J; Chen J; Yu J; Wang D; Wakimoto H; Gong Y; Hua L J Neurosurg; 2024 Sep; 141(3):593-601. PubMed ID: 38552238 [TBL] [Abstract][Full Text] [Related]
13. Identification of novel therapeutic targets through genomic analysis of meningiomas. Komotar RJ; Starke RM; Connolly ES Neurosurgery; 2013 Aug; 73(2):N22-4. PubMed ID: 23867274 [No Abstract] [Full Text] [Related]
14. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Abedalthagafi M; Bi WL; Aizer AA; Merrill PH; Brewster R; Agarwalla PK; Listewnik ML; Dias-Santagata D; Thorner AR; Van Hummelen P; Brastianos PK; Reardon DA; Wen PY; Al-Mefty O; Ramkissoon SH; Folkerth RD; Ligon KL; Ligon AH; Alexander BM; Dunn IF; Beroukhim R; Santagata S Neuro Oncol; 2016 May; 18(5):649-55. PubMed ID: 26826201 [TBL] [Abstract][Full Text] [Related]
15. Diagnostic potential of magnetic resonance in cases of foramen magnum meningiomas. Wagle VG; Villemure JG; Melanson D; Ethier R; Bertrand G; Feindel W Neurosurgery; 1987 Nov; 21(5):622-6. PubMed ID: 3696393 [TBL] [Abstract][Full Text] [Related]
16. SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas. Boetto J; Bielle F; Sanson M; Peyre M; Kalamarides M Neuro Oncol; 2017 Mar; 19(3):345-351. PubMed ID: 28082415 [TBL] [Abstract][Full Text] [Related]
17. Melanocytic tumor with GNA11 p.Q209L mutation mimicking a foramen magnum meningioma. Strom RG; Shvartsbeyn M; Rosenblum MK; Hameed MR; Nafa K; Mikolaenko I; Babu RP Clin Neurol Neurosurg; 2012 Oct; 114(8):1197-200. PubMed ID: 22421249 [No Abstract] [Full Text] [Related]
18. Diffuse midline skull base meningiomas: identification of a rare and aggressive subgroup of meningiomas. Peyre M; Feuvret L; Sanson M; Navarro S; Boch AL; Loiseau H; Kalamarides M J Neurooncol; 2017 Jul; 133(3):633-639. PubMed ID: 28536991 [TBL] [Abstract][Full Text] [Related]